Twist Bioscience (TWST) Liabilities and Shareholders Equity (2018 - 2026)

Twist Bioscience (TWST) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $672.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 4.48% year-over-year to $672.4 million in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 6.76% increase from a year earlier, with the FY2025 full-year figure at $641.9 million, up 4.48% from the prior year.
• Liabilities and Shareholders Equity was $672.4 million for Q2 2026 at Twist Bioscience, down from $676.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.0 billion in Q1 2022 and troughed at $595.6 million in Q1 2025.
• A 5-year average of $748.8 million and a median of $689.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 50.84% in 2022 and fell 21.25% in 2024, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $910.0 million in 2022, then decreased by 19.47% to $732.8 million in 2023, then declined by 16.95% to $608.6 million in 2024, then advanced by 4.85% to $638.1 million in 2025, then rose by 5.38% to $672.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $672.4 million (Q2 2026), $676.2 million (Q1 2026), and $638.1 million (Q4 2025), per Business Quant data.